David Kent
Dr. David Kent is a Principal Investigator at the York Biomedical Research Institute (https://www.york.ac.uk/biology/research/infection-immunity/david-kent/). His laboratory's research focuses on the fundamental biology of blood stem cells and how changes in their regulation lead to cancers. David has a long history of public engagement and outreach including the creation of The Black Hole (https://www.universityaffairs.ca/opinion/the-black-hole/) in 2009. He has been writing for Signals since 2010.
Posts by: David
Obtaining more target cells for gene therapy
Blood stem cells are the fundamental component of regenerative medicine applications involving the blood and immune system. Despite significant efforts and investment, the research community has largely failed to maintain fully functional blood stem cells for substantial periods of time outside the body. As a result, the limiting factor for cell and gene therapies is […]
Blood stem cell gene therapy – the comeback kid of experimental medicine
Over the coming weeks, I will be writing a series of blog entries on gene therapy using blood stem cells as a base cellular product. In the last few years we have witnessed an incredible return to the headlines for gene therapy now that safer, more accurate tools have been developed and clinical trials for a […]
Effective workshop structure: Exploiting the ties that bind
In October, I participated in a workshop hosted by Medicine by Design (MbD) in Toronto. The workshop was right up my alley – blood stem cells and clonal evolution – but I’ll spare the Signals readership the specific details.* Rather, today’s post focuses on the bigger picture of why scientists need such workshops and how critical […]